Palliative care for end-stage lung disease patients

Clinical Pulmonary Medicine

Volumn 10, Issue 5, 2003, Pages 269-277

  Varkey, Basil ^a  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Bronchodilators; End stage lung disease; Hospice care; Opiods; Palliative care

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUSPIRONE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CODEINE; DESIPRAMINE; DIAMORPHINE; DIAZEPAM; DIHYDROCODEINE; DOXEPIN; FORMOTEROL; IPRATROPIUM BROMIDE; LAXATIVE; METHADONE; METHYLPHENIDATE; MORPHINE; NORTRIPTYLINE; OPIATE; OXYGEN; PAROXETINE; PHENOTHIAZINE DERIVATIVE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNINDEXED DRUG; ZOLPIDEM;

ANXIETY DISORDER; ARTERIAL CARBON DIOXIDE TENSION; CLINICAL TRIAL; CONSTIPATION; COUGHING; DELIRIUM; DEPRESSION; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DROWSINESS; DRUG USE; DYSPNEA; HOME CARE; HUMAN; INFORMED CONSENT; INSOMNIA; INTERPERSONAL COMMUNICATION; LUNG INSUFFICIENCY; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MUSCLE TRAINING; NAUSEA; OXYGEN SATURATION; OXYGEN TENSION; OXYGEN THERAPY; PALLIATIVE THERAPY; PHYSICIAN ATTITUDE; QUALITY OF LIFE; REVIEW; SYMPTOM; TERMINAL CARE; TERMINAL DISEASE; TREATMENT PLANNING; VOMITING; XEROSTOMIA;

EID: 0141452205     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000087522.30432.c2     Document Type: Review

References (90)

1. Edmonds P, Karlsen S, Khan S, et al. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliat Med. 2001;15:287-295.
2. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? a comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55:1000-1006.
3. Hill KM, Muers MF. Palliative care for patients with non-malignant end stage respiratory disease. Thorax. 2000;55:979-981.
4. Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med. 1996;335:172-178.
5. World Health Organization. Cancer Pain Relief and Palliative Care. Geneva, Switzerland: World Health Organization; 1990;11-12.
6. Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. JAMA. 1999;282:1638-1645.
7. Manaker S, Tino G. Natural history and prognosis of advanced lung disease. Clin Chest Med. 1997;18:435-455.
8. Lynn J, Harrell F, Cohn F, et al. Prognosis of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. New Horiz. 1997;5:56-61.
9. Bjoraker JA, Ryuv H, Edwin MK, et al. Prognostic significance of histopathologic subsets of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199-203.
10. Heffner JE, Fahy B, Hilling L, et al. Attitudes regarding advance directives among patients in pulmonary rehabilitation. Am J Respir Crit Care Med. 1996;154:1735-1740.
11. Blackhall W, Murphy ST, Frank G, et al. Ethnicity and attitude toward patient autonomy. JAMA. 1995;274:820-825.
12. Danis M, Mutram E, Garrett JM, et al. A prospective study of the impact of patient preferences on life-sustaining treatment and hospital cost. Crit Care Med. 1996;24:1811-1817.
13. Schneiderman LN, Pearlman RA, Kaplan RM, et al. Relationship of general advance directive instructions to specific life-sustaining treatment preferences in patients with serious illness. Arch Intern Med. 1992;152:2114-2122.
14. Hansen-Flaschen JH. Palliative home care for advanced lung disease. Respir Care. 2000;45:1478-1486.
15. Abrahm JL, Hansen-Flaschen J. Hospice care for patients with advanced lung disease. Chest. 2002;121:220-229.
16. Health Care Financing Administration. Covered services. Hospice manual, chapter 2. Medicare and Medicaid manual. Publication No. 21. Available at: http://www.hcfa.gov/pubforms/htmltoc.htm.
17. Determining terminal status in non-cancer diagnoses: pulmonary disease. Medicare Part A. Intermediary hospice medical policy manual. Effective 8/1/98; revised 6/1/00. Available at: http://www.iamedicare.com/provider/lmrp/meda.htm.
18. Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. JAMA. 1999;282:1638-1645.
19. Schonwetter RS, Soendker S, Perron V, et al. Review of Medicare's proposed hospice eligibility criteria for select noncancer patients. Am J Hosp Palliat Care. 1998;15:155-158.
20. Emanuel EJ, Fairclough DL, Slutzman J, et al. Assistance from family members, friends, paid care givers and volunteers in the care of terminally ill patients. N Engl J Med. 1999;341:956-963.
21. Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990;142:1009-1014.
22. O'Donnell DE. Breathlessness in patients with chronic airflow limitation. Chest. 1994;106:904-912.
23. Tobin MJ. Dyspnea: pathophysiologic basis, clinical presentation, and management. Arch Intern Med. 1990;150:1604-1613.
24. American Thoracic Society. Dyspnea: mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321-340.
25. Janssens JP, de Muralt B, Titelion V. Management of dyspnea in severe chronic obstructive pulmonary disease. J Pain Symptom Manage. 2000; 19:378-392.
26. Hajiiro T, Nishimura K, Tsukino M, et al. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life in patients with COPD. Chest. 1999;116:1632-1637.
27. Sorenson, Helen M. Dyspnea assessment. Respir Care. 2000;45:1331-1341.
28. Eltayara L, Becklake MR, Volta CA, et al. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:1726-1734.
29. O'Donnell DE, Webb KA. Breathlessness in patients with severe chronic airflow limitation. Chest. 1992;102:824-831.
30. Lareau SC, Meek PM, Press D, et al. Dyspnea in patients with chronic obstructive pulmonary disease: does dyspnea worsen longitudinally in the presence of declining lung function? Heart Lung. 1999;28:65-73.
31. Wolkove N, Dajczman E, Colacone A, et al. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest. 1989;96:1247-1251.
32. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-381.
33. Jennings AL, Davies AN, Higgins JPT, et al. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev. 2002;4:1-33.
34. Enck RE. The role of nebulized morphine in managing dyspnea. Am J Hosp Palliat Care. 1999;16:373-374.
35. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66:2221-2331.
36. Rogers DF, Barnes PJ. Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet. 1989;1:930-932.
37. Adcock JJ. Peripheral opioid receptors and the cough reflex. Respir Med. 1991;85:43-46.
38. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1877-1880.
39. Cohen MH, Anderson AJ, Krasnow SH, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J. 1991;84:229-234.
40. Sorenson HM. Managing secretions in dying patients. Respir Care. 2000;45:1355-1362.
41. Pellegrino ED. Emerging ethical issues in palliative care. JAMA. 1998; 279:1521-1522.
42. Davidson AC, Leach R, George RJD, et al. Supplemental oxygen and exercise ability in chronic obstructive airways disease. Thorax. 1988; 43:965-971.
43. Woodcock AAS, Gross ER, Geddes DM. Oxygen relieves breathlessness in pink puffers. Lancet. 1981;1:907-909.
44. Dean NC, Brown JK, Himelman RB, et al. Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. Am Rev Respir Dis. 1992;146:941-945.
45. Swinburn CR, Mould H, Stone TN, et al. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis. 1991;143:913-915.
46. Liss HP, Grant BJB. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1988;137:1285-1288.
47. Sestini P, Renzoni E, Robinson S, et al. Short acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:1-13.
48. Guyatt GH, Townsend M, Keller JL, et al. Should study subjects see their previous responses: data from a randomized control trial. J Clin Epidemiol. 1989;42:913-920.
49. Appleton S, Poole P, Smith, B, et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. 2002;4:1-37.
50. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dysponea in COPD. Eur Respir J. 2001;17:1132-1137.
51. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122: 47-55.
52. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994;105:1411-1419.
53. Ram FSF, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:1-51.
54. Yellowlees PM, Alpers JH, Bowden JJ, et al. Psychiatric morbidity in patients with chronic airflow obstruction. Med J Aust. 1987;146:305-307.
55. Mitchell-Heggs P, Murphy K, Minty K, et al. Diazepam in the treatment of dyspnoea in the "Pink Puffer" syndrome. Q J Med. 1980;49:9-20.
56. Green JG, Pucino F, Carlson JD, et al. Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacotherapy. 1989;9:34-38.
57. Woodcock AA, Gross ER, Geddes DM, et al. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J (Clin Res Ed). 1981;283:343-346.
58. Eimer M, Cable T, Gal P, et al. Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. J Fam Pract. 1985;21:359-362.
59. Man GC, Hsu K, Sproule BJ, et al. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest. 1986;90:832-836.
60. Argyropoulou P, Patakas D, Koukou A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration. 1993;60:216-220.
61. Light RW, Merrill EJ, Despars J, et al. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146:1377-1380.
62. Popkin MK, Callies AL, Mackenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry. 1985;42:1160-1163.
63. Borson S, McDonald GJ, Gayle T, et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33:190-201.
64. Gordon GH, Michiels TM, Mahutte CK, et al. Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease. Psychiatry Res. 1985;15:25-32.
65. Ries AL, Kaplan RM, Limberg TM, et al. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995;122:823-832.
66. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996; 348:1115-1119.
67. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest. 2000;117:976-983.
68. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. Chest. 1997;112:1363-1396.
69. Wedzicha JA, Bestall JC, Garrod R, et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J. 1998;12:363-369.
70. Garrod R, Mikelsons C, Paul EA, et al. Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1335-1341.
71. Smith K, Cook D, Guyatt GH, et al. Respiratory muscle training in chronic airflow limitation: a meta-analysis. Am Rev Respir Dis. 1992; 145:533-539.
72. Berry MJ, Adair NE, Sevensky KS, et al. Inspiratory muscle training and wholebody reconditioning in chronic obstructive pulmonary disease: a controlled randomized trial. Am J Respir Crit Care Med. 1996;153: 1812-1816.
73. Weiner P, Magadle R, Berar-Yanay N, et al. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest. 2000;118:672-678.
74. Riera HS, Rubio TM, Ruiz FO, et al. Inspiratory muscle training in patients with COPD. Chest. 2001;120:748-756.
75. Covey MK, Larson JL, Wirtz SE, et al. High-intensity inspiratory muscle training in patients with chronic obstructive pulmonary disease and severely reduced function. Cardiopulm Rehab. 2001;21:231-240.
76. International Consensus Conferences in Intensive Care Medicine. Noninvasive positive pressure ventilation in acute respiratory failure: consensus statement of indications and benefit of NIPPV during COPD exacerbations. Am J Respir Crit Care Med. 2001;163:283-291.
77. Hill NS, Eveloff SE, Carlisle CC, et al. Efficacy of nocturnal-nasal ventilation in patients with restrictive thoracic disease. Am Rev Respir Dis. 1992;145:365-371.
78. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996;139(Suppl):123-128.
79. Lyall RA, Fleming TA, Newsome-Davis I, et al. A prospective controlled study of the effect of noninvasive positive pressure ventilation (NIPPV) on quality of life in ALS (abstract). Am J Respir Crit Care Med. 2000;161:A358.
80. Hill NS. Complications of noninvasive ventilation [editorial]. Respir Care. 2000;45:480-481.
81. Clarke DE, Vaughan L, Raffin TA. Noninvasive positive pressure ventilation for patients with terminal respiratory failure: the ethical and economic costs of delaying the inevitable are too great [editorial]. Am J Crit Care. 1994;3:4-5.
82. Benditt JO. Noninvasive ventilation at the end of life. Respir Care. 2000;45:1376-1381.
83. Smith B, Appleton S, Adams R, et al. Home care by outreach nursing for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;1-16.
84. Pan CX, Morrison RS, Ness J, et al. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near end of life: a systematic review. Pain Symptom Manage. 2000;20: 374-387.
85. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med. 1995;9:307-313.
86. Davies SF, McQuaid KR, Iber C, et al. Extreme dyspnea from unilateral pulmonary venous obstruction: demonstration of a vagal mechanism and relief by right vagotomy. Am Rev Respir Dis. 1987;136:184-188.
87. Doyle D, Hank GWC, MacDonald NOxford Textbook of Palliative Medicine, 2nd edition. Oxford University Press; 1998;601-622.
88. Irwin RS, Madison JM. The persistently troublesome cough. Am J Respir Crit Care Med. 2002;165:1469-1474.
89. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2000(2): DC001287.
90. Girault C, Muir JF, Mihaltan F, et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest. 1996; 110:1203-1211.